<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521560</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2004-R4</org_study_id>
    <secondary_id>DSHNHL 2004-R4</secondary_id>
    <nct_id>NCT00521560</nct_id>
  </id_info>
  <brief_title>A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas</brief_title>
  <acronym>escZ-BEAM</acronym>
  <official_title>Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy with simultaneous
      application of Zevalin and BEAM followed by autologous peripheral stem cell transplantation
      in relapsed and refractory CD 20+ Non-Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable is the highest achievable dose level of 90Y-Zevalin administered immediately before BEAM high-dose therapy and followed by autologous stem cell transplantation.</measure>
    <time_frame>3 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality (TRM), freedom from progression (FFP), Survival (OS), progression free survival (PFS) grade III -IV toxicity (CTC) on lung, liver and kidney</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Primary Non-Hodgkin-Lymphoma</condition>
  <condition>Refractory Non-Hodgkin-Lymphoma</condition>
  <condition>CD20+ Aggressive Non-Hodgkin`s Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zevalin</intervention_name>
    <description>All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.
High dose therapy will be given as BEAM</description>
    <arm_group_label>1</arm_group_label>
    <other_name>90Y-Ibritumomab-Tiuxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 65 years

          -  Risk group: 1) Progression on primary therapy 2) Initial or subsequent relapse

          -  Histology: Diagnosis of relapsed aggressive non-Hodgkin lymphoma, whenever possible
             confirmed by an excision biopsy of a lymph node or by a sufficiently large biopsy of
             an extranodal site if no lymph node lesion is present. The expression of the CD20
             antigen must be demonstrated in the primary lesion or in the relapse. Specifically,
             the following entities can be treated in this study:

        B-NHL:

        Grade III B follicular lymphoma Diffuse B-cell lymphoma centroblastic immunoblastic
        plasmoblastic anaplastic-large-cell T-cell rich B-cell lymphoma Primary effusion lymphoma
        Intravascular B-cell lymphoma Primary mediastinal B-cell lymphoma Mantle cell lymphoma,
        blastoid Variants of Burkitt's lymphoma Aggressive marginal zone lymphoma (monocytoid)

          -  General condition: General condition ECOG 0-3 (Karnofsky: 40 - 100 %); for definition
             see Annex 14.10

          -  Presence of declaration of participation of the center and the patient's written
             consent form

        Exclusion Criteria:

          -  Prior mediastinal or extensive abdominal irradiation

          -  Prior high-dose therapy and autologous stem cell transplantation

          -  Impairment of renal function (creatinine &gt; 2.5 mg/dL, creatinine clearance &lt; 20
             mL/min)

          -  Impairment of hepatic function (bilirubin &gt; 2.0 mg/dL, cholinesterase [CHE] &lt; 2000
             U/L)

          -  Impairment of pulmonary function (transfer lung factor for CO [TLCO] &lt; 50 %, forced
             expiratory volume in 1 sec [FEV1] &lt; 60 %, vital capacity [VC] &lt; 60 %)

          -  Relevant deterioration of the above organ functions on salvage therapy

          -  Failure of stem cell mobilization

          -  Active viral hepatitis

          -  HIV infection

          -  Other active or not conclusively curatively treated malignoma

          -  Severe concomitant psychiatric illness or suspected lack of patient compliance

          -  Pregnancy or unreliable contraception

          -  Highly dynamic progress of lymphoma (lactate dehydrogenase [LDH] &gt; 1.5 x upper limit
             of normal [ULN]) after salvage therapy immediately prior to radioimmunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glass, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>German Society of Cancer e.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Gramatzki, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtisches Krankenhaus Kiel, II. Med. Uniklinik, Kiel, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mattias Witzens Harig, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abteilung Innere Medizin V, Hämatologie, Onkologie, Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Hertenstein, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Bremen-Mitte gGmbH, Medizinische Klinik I, Bremen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Heß, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>III Med., Schwerpunkt Hämatologie / Onkologie, Mainz, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorothea Kofahl-Krause, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MHH, Hämatologie, Hämostaseologie und Onkologie, Hannover, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Schmitz, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg, Hämatologische Abt., Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jörg Schubert, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätskliniken d. Saarlandes, Med. I, Homburg/Saar, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lutz Uharek Uharek, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité - Campus Benjamin Franklin, Med. III, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für anwendungsorientierte Forschung und klinische Studien (IFS GmbH)</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-Dose Radio-Immuno- and Chemotherapy</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>90Y-Ibritumomab-Tiuxetan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

